for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Dicerna Pharmaceuticals Inc

DRNA.OQ

Latest Trade

14.43USD

Change

0.09(+0.63%)

Volume

108,618

Today's Range

14.33

 - 

14.58

52 Week Range

9.40

 - 

17.04

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.34
Open
14.37
Volume
108,618
3M AVG Volume
8.15
Today's High
14.58
Today's Low
14.33
52 Week High
17.04
52 Week Low
9.40
Shares Out (MIL)
68.36
Market Cap (MIL)
980.28
Forward P/E
-10.74
Dividend (Yield %)
--

Next Event

Dicerna Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Dicerna Q2 Loss Per Share $0.35

Dicerna Receives Breakthrough Therapy Designation For Dcr-Phxc

Dicerna To Begin Clinical Development Of DCR-A1AT For Treatment Of Patients With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.

Industry

Biotechnology & Drugs

Contact Info

87 Cambridgepark Dr

+1.617.6218097

http://www.dicerna.com/

Executive Leadership

J. Kevin Buchi

Independent Chairman of the Board

Douglas M. Fambrough

President, Chief Executive Officer, Director

John B. Green

Chief Financial Officer, Principal Financial Officer

Bob D. Brown

Senior Vice President, Chief Scientific Officer

Regina DeTore Paglia

Senior Vice President of Human Resources

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-2.870

2017

-3.660

2018

-1.600

2019(E)

-1.335
Price To Earnings (TTM)
--
Price To Sales (TTM)
82.55
Price To Book (MRQ)
6.12
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-51.70
Return on Equity (TTM)
-38.85

Latest News

Eli Lilly makes bet on gene-silencing drug firm Dicerna

Eli Lilly and Co <LLY.N> is spending $100 million for a stake in Dicerna Pharmaceuticals Inc <DRNA.O> as part of a licensing deal, making it the latest major drugmaker to bet on gene-silencing technology.

BRIEF-Dicerna Pharmaceuticals Files For Mixed Shelf Of Upto $250 Mln - SEC Filing

* DICERNA PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UPTO $250 MILLION - SEC FILING Source text: (https://bit.ly/2rQEqC9) Further company coverage:

U.S. biotech companies Alnylam, Dicerna settle trade secrets case

Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

CORRECTED-UPDATE 1-U.S. biotech companies Alnylam, Dicerna settle trade secrets case

Dicerna Pharmaceuticals Inc on Friday said that it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

CORRECTED-Biotech companies Alnylam, Dicerna settle trade secrets case

Dicerna Pharmaceuticals Inc on Friday said it will pay $15 million plus stock to Alnylam Pharmaceuticals Inc to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments.

BRIEF-Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals

* ALNYLAM REACHES SETTLEMENT AGREEMENT WITH DICERNA PHARMACEUTICALS RESOLVING TRADE SECRET MISAPPROPRIATION AND OTHER PENDING LITIGATION

BRIEF-Dicerna Pharma Files ‍Prospectus Related To Offering

* DICERNA PHARMACEUTICALS INC FILES PROSPECTUS RELATED TO OFFERING UP TO 24.5 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2FKmcfn) Further company coverage:

BRIEF-Dicerna Reports Qtrly Loss Per Share Of $0.90

* DICERNA REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Ecor1 Capital Llc Reports a 9.4 Percent Passive Stake In Dicerna Pharmaceuticals

* ECOR1 CAPITAL, LLC REPORTS A 9.4 PERCENT PASSIVE STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 20, 2017 Source text: (http://bit.ly/2Ac7p5t) Further company coverage:

BRIEF-RA Capital Management LLC Reports 9.9 Pct Stake In Dicerna Pharmaceuticals

* RA CAPITAL MANAGEMENT LLC REPORTS 9.9 PERCENT STAKE IN DICERNA PHARMACEUTICALS AS OF DEC 18 - SEC FILING

BRIEF-Bain Capital Life Sciences Fund Reports 15.7 Percent Stake In Dicerna Pharmaceuticals

* BAIN CAPITAL LIFE SCIENCES FUND L.P. REPORTS 15.7 PERCENT STAKE IN DICERNA PHARMACEUTICALS INC AS ON DEC 18 - SEC FILING

BRIEF-Dicerna Announces Pricing Of Follow-On Public Offering Of Common Stock

* DICERNA ANNOUNCES PRICING OF FOLLOW-ON PUBLIC OFFERING OF COMMON STOCK

BRIEF-Dicerna Pharmaceuticals Files Preliminary Prospectus Supplement Related To A Potential Common Stock Offering

* DICERNA PHARMACEUTICALS INC FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO A POTENTIAL COMMON STOCK OFFERING - SEC FILING Source text : (http://bit.ly/2o22t2b) Further company coverage:

BRIEF-Dicerna announces proposed public offering of common stock

* DICERNA PHARMACEUTICALS INC - TO USE PROCEEDS FROM OFFERING FOR PRECLINICAL STUDIES & CLINICAL TRIALS Source text for Eikon: Further company coverage:

BRIEF-Dicerna Announces First Human Dosed In Phase 1 Clinical Trial Of DCR-PHXC

* DICERNA ANNOUNCES FIRST HUMAN DOSED IN PHASE 1 CLINICAL TRIAL OF DCR-PHXC FOR TREATMENT OF ALL FORMS OF PRIMARY HYPEROXALURIA

BRIEF-Dicerna Pharmaceuticals Q3 loss per share ‍$0.92

* Q3 2017 loss per share $0.92 Source text for Eikon: Further company coverage:

BRIEF-Boehringer, Dicerna collaborate to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis

* Boehringer Ingelheim and Dicerna announce collaboration to develop novel treatments for chronic liver diseases including nonalcoholic steatohepatitis (NASH)

BRIEF-Dicerna files clinical trial application for DCR-PHXC for phase 1 study in hyperoxaluria

* Dicerna files clinical trial application for DCR-PHXC, the company’s most advanced GalXC™ product candidate, for phase 1 study in primary hyperoxaluria (ph)

BRIEF-Dicerna Q2 net loss per share $1.15

* Dicerna reports second quarter 2017 financial and operating results and provides corporate update

BRIEF-Dicerna Pharmaceuticals reports Q1 loss per share $0.68

* Dicerna reports first quarter 2017 financial and operational results and provides corporate update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up